TL;DR
Former executives of an unnamed health tech company that went public via a SPAC merger have agreed to a $10 million settlement to resolve investor lawsuits. The claims alleged executives...
TL;DR
GSK is set to acquire clinical-stage biotech Rapt Therapeutics for $2.2 billion in equity, or $58 per share in cash, with a net cash commitment of $1.9 billion. This acquisition grants GSK...
TL;DR
AstraZeneca's CFO outlined a disciplined M&A strategy, prioritizing bolt-on acquisitions under $5 billion in oncology and rare diseases, while actively scouting for preclinical assets in...
Sanofi is revising its takeover offer for Ocular Therapeutix after the U.S. biotech rejected the French drugmaker's initial $16 per share proposal, according to recent filings and market reports. ...
```html Boston Scientific Acquires Penumbra In $14.5 Billion Bet To Dominate Thrombectomy body { font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', 'Helvetica Neue', sans-serif; line-height:...
Johnson & Johnson (NYSE: JNJ) secured a partial victory from Delaware's Supreme Court, overturning a key element of a $1 billion damages award tied to its 2019 $3.4 billion acquisition of...
Medtronic is aggressively pursuing **tuck-in M&A** in the **low- to mid-single-digit billion-dollar range**, targeting cardiology and neuroscience to accelerate growth amid a resurgent **MedTech M&A...
A U.S. District Court ruling on January 9, 2026, has permanently halted Edwards Lifesciences' proposed $945 million to $1.2 billion acquisition of JenaValve Technology, following a Federal Trade...
Eli Lilly’s $1.2 billion all-cash acquisition of Ventyx Biosciences is a targeted move to secure a differentiated, oral NLRP3 franchise and expand its footprint across cardiometabolic,...
```html AbbVie Inc. is in advanced talks to acquire Revolution Medicines, a clinical-stage precision oncology company, in a deal valued at approximately $20 billion or more—a significant premium to...
